Literature DB >> 3230724

Peritoneovenous shunting for intractable cirrhotic and cancerous ascites using different types of shunting tubes.

K Akimaru1, Y Ueda, T Shoji.   

Abstract

A total of twenty six peritoneovenous shuntings were performed in our department between 1978 and 1984, on twelve cirrhotic and ten cancerous patients with intractable ascites, using Pudenz, LeVeen or Denver type shunting tubes. Reduced ascites was noted postoperatively with statistical significance in both the cirrhotic group (p less than 0.05) and the cancerous group (p less than 0.01), of whom eight cirrhotic and seven cancerous patients exhibited an abdominal girth reduced by 9.7 cm (a 10.9 per cent reduction) in two weeks. A larger urinary output was noted in 13 patients, with a mean increase of 587 ml/day compared with the pre-shunting output. These patients lost a mean weight of 6.13 kg in two weeks, while the nonreduced ascites group gained weight. The post-shunting serum albumin level was higher in the reduced ascites group. The mean functioning periods of the shunts were 5.1 and 2 months, respectively for the cirrhotic and cancerous patients whose shunts were patent. The patients' outcome was shown to depend on the disease itself, with the exception of one patient who died of disseminated intravascular coagulopathy following shunting. In comparing several types of shunting systems, the Denver-type was proven as being the most unlikely to plug or malfunction because of its simpler structure.

Entities:  

Mesh:

Year:  1988        PMID: 3230724     DOI: 10.1007/bf02471482

Source DB:  PubMed          Journal:  Jpn J Surg        ISSN: 0047-1909


  24 in total

1.  Further experience with peritoneo-venous shunt for ascites.

Authors:  H H LeVeen; S Wapnick; S Grosberg; M J Kinney
Journal:  Ann Surg       Date:  1976-11       Impact factor: 12.969

2.  Radionuclide assessment of LeVeen shunt patency.

Authors:  N Kirchmer; U Hart
Journal:  Ann Surg       Date:  1977-02       Impact factor: 12.969

3.  Subcutaneous cancer growth complicating the peritoneovenous shunting of malignant ascites.

Authors:  A Berger; M I Goldberg
Journal:  Surgery       Date:  1983-03       Impact factor: 3.982

4.  Peritoneovenous shunting in patients with malignant ascites.

Authors:  J M Holman; D Albo
Journal:  Am J Surg       Date:  1981-12       Impact factor: 2.565

5.  [Coagulant and procoagulant factors in ascitic fluid--about etiology DIC induced by ascitic fluid infusion (author's transl)].

Authors:  M Ojiro
Journal:  Igaku Kenkyu       Date:  1981-10

6.  Intractable ascites treated with peritoneovenous shunts (LeVeen). A 24- to 64-month follow-up of results in 52 alcoholic cirrhotics.

Authors:  H B Greenlee; M M Stanley; G F Reinhardt
Journal:  Arch Surg       Date:  1981-05

7.  Palliation of malignant ascites by the LeVeen peritoneo-venous shunt.

Authors:  J H Raaf; J R Stroehlein
Journal:  Cancer       Date:  1980-03-01       Impact factor: 6.860

8.  Peritoneovenous shunting for ascites in cancer patients.

Authors:  J Oosterlee
Journal:  Br J Surg       Date:  1980-09       Impact factor: 6.939

9.  Bizarre complications of peritoneovenous shunts.

Authors:  F E Eckhauser; W E Strodel; J W Girardy; J G Turcotte
Journal:  Ann Surg       Date:  1981-02       Impact factor: 12.969

10.  Superior vena caval obstruction associated with long-term peritoneovenous shunting.

Authors:  F E Eckhauser; W E Strodel; J A Knol; J G Turcotte
Journal:  Ann Surg       Date:  1979-12       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.